key: cord-0773040-2ig961lu authors: Lee, K. A.; Ma, W.; Sikavi, D. R.; Wolf, J.; Steves, C. J.; Spector, T. D.; Chan, A. T. title: Cancer and risk of COVID-19 through a general community survey date: 2020-05-26 journal: nan DOI: 10.1101/2020.05.20.20103762 sha: 9d2e9a500a4a892c67611f9f8b048d7fc2ab072d doc_id: 773040 cord_uid: 2ig961lu Background: Data are limited on the risk of coronavirus disease 2019 (COVID-19) among individuals with cancer and whether cancer-related therapy exacerbates this risk. Methods: We evaluated the risk for coronavirus disease 2019 (COVID-19) among patients living with cancer compared to the general community and whether cancer-related treatments influence this risk. Data were collected from the COVID Symptom Study smartphone application since March 24, 2020 (United Kingdom), March 29 (U.S.), and April 29, 2020 (Sweden) through May 8, 2020. We used multivariate-adjusted odds ratios (aORs) of a positive COVID-19 test as well as predicted COVID-19 infection using a validated symptom model. Results: Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared to participants without cancer, those living with cancer had 62% increased risk of a positive COVID-19 test (95% CI: 1.37-1.91). Among patients with cancer, current treatment with chemotherapy/immunotherapy was associated with a nearly 2.5-fold increased risk of a positive test (aOR: 2.42; 95% CI: 1.81-3.25). The association between cancer and COVID-19+ was stronger among participants >65 years (aOR: 1.93; 95%CI: 1.51-2.46) compared to younger participants (aOR: 1.32; 95%CI: 1.06-1.64; Pinteraction<0.001); and among males (aOR: 1.71; 95%CI: 1.36-2.15) compared to females (aOR: 1.43; 95%CI: 1.14-1.79; Pinteraction=0.02). Conclusions: Individuals with cancer had a significantly increased risk of infection compared to the general community. Those treated with chemotherapy or immunotherapy were particularly at-risk of infection. Trial Registration: ClinicalTrials.gov NCT04331509 Individuals with cancer may be at higher risk for coronavirus disease 2019 (COVID-19). However, data are limited largely to small studies conducted among hospitalized patients. We recruited individuals from the general population in the United Kingdom, United States, and Sweden using The COVID Symptom Study, a freely available smartphone application developed by Zoe Global Ltd. in collaboration with the Massachusetts General Hospital and King's College London offering a guided interface to report a range of baseline demographic information and comorbidities as previously reported. 1 Participants are encouraged to use the application daily to report symptoms and COVID-19 testing results. We queried if individuals were living with cancer (yes/no) and if they were on chemotherapy or immunotherapy (yes/no) beginning on March 29, 2020. We employed multivariable logistic regression models to examine the association between cancer and risk of a positive COVID-19 test (COVID-19+). We separately analyzed the risk associated with chemotherapy/immunotherapy for COVID-19+ among individuals with cancer. Two-sided p-values<0.05 were considered statistically significant. All analyses were performed using R 3.6.1 (Vienna, Austria). Through May 8, 2020, 1,807,559 participants provided demographic and longitudinal symptom and testing information. Compared to individuals without cancer, those with cancer were older, more frequently male, and more commonly overweight/obese, among other comorbidities ( Table 1) . They were more likely to use several common medications and have health problems requiring them to stay . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Among >1.8 million participants, we found that individuals living with cancer had a 60% increased risk of COVID-19+ or hospitalization with COVID-19, with greater risks for older individuals or those receiving anti-cancer therapies. Prior studies have shown that individuals with cancer comprise a disproportionate share of poorer COVID-19 outcomes, 3-6 including death. However, these studies had small sample sizes and are largely based on hospitalized patients, capturing the most severe cases. Individuals living with cancer also tend to be older with greater comorbidities that predispose to hospitalization and adverse events. Our results from a large, community-based sample support that incidence of infection, including milder disease with more limited symptoms, is also higher in individuals with cancer. Our study was limited by the use of self-reported information collected from individuals who used smartphone devices. Covid-19 testing was not based on uniform screening. However, the current shortage of PCR-based testing kits in both the U.K. and the U.S. does not make such an . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20103762 doi: medRxiv preprint approach feasible. We had limited data on specific tumor types and treatment regimens. We are planning future studies collecting more detailed information from individuals with cancer with linkage to other data sources. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. JW is an employee of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. ATC previously served as an investigator on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd. Other authors have no conflict of interest to declare. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . Data collected in the app are being shared with other health researchers through the NHS-funded Health Data Research UK (HDRUK)/SAIL consortium, housed in the UK Secure e-Research Platform (UKSeRP) in Swansea. Anonymized data collected by the symptom tracker app can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). US investigators are encouraged to coordinate data requests through the COPE Consortium (www.monganinstitute.org/cope-consortium). Data updates can be found at https://covid.joinzoe.com. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Abbreviations: ACE (angiotensin converting enzyme), NSAIDs (non-steroidal anti-inflammatory drugs). Proportions are calculated based on the total number of participants with available data. History of cancer, uses of aspirin and NSAIDs, and smoking status have been queried since launch in the U.S. and Sweden and since 3/29/2020 in the U.K. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . a Immunosuppressant medications including steroids, methotrexate, biologics were asked. b Limited mobility was asked as "In general, do you have any health problems that require you to stay at home?" . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . ≥ 30 kg/m 2 ), sex, history of diabetes, heart disease, lung disease, kidney disease, and current smoker status. Interaction was assessed by evaluating the significance of the cross-product terms of cancer and these factors using the Wald test. Models were adjusted for variables as above except for the factor that was stratified for. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint Rapid implementation of mobile technology for real-time epidemiology of COVID-19 Real-time tracking of self-reported symptoms to predict potential COVID-19 Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv